Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy. Richard Staines met with representatives of the company at the European Society for Medical Oncology (ESMO) conference to find out more.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,